DSM taps Amyris for nutritional ingredient

In California, Amyris and DSM have entered into their first product development and production deal for a food and nutrition molecule made via Amyris’ fermentation technology.

DSM, a major player in food and nutrition, recently made an equity investment in Amyris. The deal announced today includes unspecified funding by DSM for Amyris to scale and produce a specific ingredient. It is expected to be the first of several such development agreements

“This is the first of what are expected to be several highly disruptive products addressing major markets where, together, we can leverage Amyris’s technology platform to reduce cost for products DSM then takes to market in a cost-advantaged position,” said John Melo, Amyris President and CEO.